Navigation Links
Pivotal Data Showed SYMBICORT(R) Improved Lung Function in Adults with COPD
Date:10/29/2008

CLA). "Data from these trials also showed that a greater percentage of patients achieved a 15 percent improvement in FEV1 within 15 minutes with SYMBICORT as compared to budesonide and placebo on the day of randomization and end of treatment."(5)

SHINE Study Results (Abstracts 298 and SHINE Safety)

The efficacy and tolerability of SYMBICORT was assessed in a six-month, randomized, double-blind, multicenter trial evaluating 1,704 patients ages 40 years and older with moderate to very severe COPD.(1,2) After two weeks of treatment based on previous therapy (inhaled corticosteroids (ICS) and short-acting bronchodilators were allowed), patients were then randomized to receive twice-daily treatment with two inhalations of SYMBICORT pMDI 160/4.5 micrograms (mcg), SYMBICORT pMDI 80/4.5 mcg, budesonide pMDI 160 mcg + formoterol DPI 4.5 mcg, budesonide pMDI 160 mcg, formoterol DPI 4.5 mcg or placebo.(1,2) Study results include:

-- Both SYMBICORT doses (160/4.5 and 80/4.5 mcg) demonstrated a significantly greater improvement from baseline in pre-dose forced expiratory volume in one second (FEV1) (P Less Than or Equal To .001) and one-hour post-dose FEV1 compared with budesonide (P<.001).(1)

-- SYMBICORT 160/4.5 mcg also demonstrated a significant (P=.026) improvement from baseline for pre-dose FEV1 compared with formoterol.(1)

-- Improvements from baseline in morning and evening peak expiratory flow (PEF) were significantly (P Less Than or Equal To .016) greater for both SYMBICORT doses compared with formoterol, budesonide and placebo.(1)

-- Both SYMBICORT doses significantly (P<.028) improved the sum of Breathlessness, Cough and Sputum Scores (BCSS), sleep score, awakening-free nights, and rescue medication use versus placebo.(1)

-- Both doses of SYMBICORT were well-tolerated for six months relative to its monocomponents and placebo.(2) The incidence of pneumonia-related adverse events were similar for all treatment arms compa
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pivotal Phase III Data Confirm the Efficacy and Safety of Arpidas Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
2. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
3. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
4. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
5. Recruitment Completed in Ofatumumab NHL Pivotal Study
6. Pivotal National Trial Uses Newest Interventional Radiology Treatment to Bust Blood Clots in Legs
7. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
8. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
9. 338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment
10. Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins
11. First DuraHeart(TM) Left Ventricular Assist System Implanted in the U.S. Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... February 27, 2015 ... Überwachungssystem für kongestive Herzinsuffizienz (CHF) in seiner ...     Die ... neuartiges Herzüberwachungssystem für Patienten mit kongestiver Herzinsuffizienz ... sie ein Finanzierungsvorhaben über 5 Mio. USD ...
(Date:2/27/2015)...  Bionik Laboratories Corp. (OTC:DWTPD), a Delaware ... acquired Bionik Laboratories, Inc., a Toronto ... qualified accredited investors of units consisting of its common ... $6.2 million. Shares of the Company,s common stock will ... the symbol "DWTPD" until FINRA,s approval of the ticker ...
(Date:2/27/2015)... NEW YORK , Feb. 27, 2015 ... DESI are increasing in applications as their ... research firm Kalorama Information.  Kalorama Information says ... MS) is the most powerful tool in ... (mass spec; MS) through its traditional techniques ...
Breaking Medicine Technology:Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3
... Medical,Technologies, Inc. (Nasdaq: RMTI ), a ... specialty pharmaceuticals focused on the end-,stage-renal-disease market ... in its Phase IIb dose-ranging study for ... drug. The Phase IIb dose-ranging study ...
... WHITE PLAINS, N.Y., Sept. 18 Millennium ... an interim analysis of a large,randomized, international ... in combination with Velcade(R) (bortezomib) showed that ... better. These patients, who are not,eligible for ...
Cached Medicine Technology:Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 2Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 3Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 4The Leukemia & Lymphoma Society is Encouraged by Promising News for Myeloma Patients 2
(Date:2/28/2015)... A study out of the University of Oxford ... the treatment of a hereditary ocular condition that leads ... Dr. Robert MacLaren, professor of ophthalmology at the University ... on January 16, 2014 , the study treated six ... mostly affects men and leads to the degeneration of ...
(Date:2/28/2015)... The Mesothelioma Applied Research Foundation (Meso ... Symposium on Malignant Mesothelioma on Monday, March 2. The ... Bethesda in Bethesda, Maryland. The following award recipients will ... the mission to cure mesothelioma. , The Klaus Brauch ... Miriam Ratner. Miriam runs the Meso Foundation’s monthly spousal ...
(Date:2/28/2015)... Louis, MO (PRWEB) February 28, 2015 ... leading provider of outsourced sales, marketing and supply ... their client, BIOTA Botanicals, is bringing its award ... Celebrated worldwide, BIOTA Botanicals’ products are specifically created ... herbal care experts, BIOTA is committed to marrying ...
(Date:2/28/2015)... FL (PRWEB) February 28, 2015 ... organization has sponsored visitor health insurance programs for visitors ... years. Most Indian elderly parents traveling to the United ... such as diabetes and blood pressure. These diseases are ... not even list them as medical conditions. There were ...
(Date:2/28/2015)... 28, 2015 Kaylie Corrigan, Outdoor Supervisor ... center , and current student obtaining her Masters degree ... a weekly forum in psychoeducation on substance use for ... AZ as part of her studies. , “Even though ... support and counseling at the high school and junior ...
Breaking Medicine News(10 mins):Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 3Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2
... (Nasdaq: NUVA ), a medical device company ... for the spine, announced today that Patrick Williams, Vice ... & Company 29th Annual Healthcare Conference at The Boston ... 18, 2009, at 8:00 a.m. ET.A live webcast of ...
... was clear: a European Research Area in which the exchange ... as natural as the free movement of goods, people, services ... there is still a long way to go in achieving ... many areas. This was apparent at the international conference "European ...
... of the European Association of Cardiovascular Prevention and Rehabilitation, ... period of heart-healthy political activity in Europe which saw ... Heart Health Charter to the European Parliament. , ... Professor Joep Perk. "Now is the time to evaluate." ...
... and NEWPORT BEACH, Calif., March 11 InstaMed pledged ... (MGMA) Project SwipeIT. This industry-wide initiative is intended ... order to drive the creation and adoption of standardized, ... MGMA currently estimates that broad use of such ...
... benefit management firms, today announced a strategic partnership with KePRO, a ... CBCA to provide an unparalleled suite of proven care management solutions ... ... March 11, 2009 -- CBCA Administrators, Inc. (CBCA), one of the ...
... Services for People around the World Affected by ... Late yesterday the U.S. Senate voted to ... fiscal year 2009. The bill, passed by ... appropriation of $900 million for the Global Fund ...
Cached Medicine News:Health News:NuVasive to Present at Cowen and Company 29th Annual Healthcare Conference 2Health News:Science as a pioneer 2Health News:Science as a pioneer 3Health News:EuroPRevent 09: Changing hearts and minds in the drive to prevent cardiovascular disease 2Health News:EuroPRevent 09: Changing hearts and minds in the drive to prevent cardiovascular disease 3Health News:InstaMed Pledges Support for Project SwipeIT with Patient ID Swipe Card Solutions for Provider Acceptance and Payer Issuance 2Health News:InstaMed Pledges Support for Project SwipeIT with Patient ID Swipe Card Solutions for Provider Acceptance and Payer Issuance 3Health News:CBCA Administrators, Inc. Announces Strategic Partnership with KePRO 2Health News:CBCA Administrators, Inc. Announces Strategic Partnership with KePRO 3Health News:Congress Approves FY2009 Omnibus Appropriations Bill with $900 Million for The Global Fund 2
Ice block will provide sufficient cooling for most normal blotting applications. Sealed block is held submerged in transfer buffer. Ice block will not spill during refreezing....
... using the Antigen-Antibody Pens-Using a proprietary and ... specialized fountain pens, called Antigen-Antibody pens-TM, that ... the blotting membranes in any form or ... colored dyes helps to see antigen being ...
... the Antigen-Antibody Pens-Using a proprietary and patented ... fountain pens, called Antigen-Antibody pens-TM, that will ... blotting membranes in any form or shape ... dyes helps to see antigen being written ...
... the Antigen-Antibody Pens-Using a proprietary and patented ... fountain pens, called Antigen-Antibody pens-TM, that will ... blotting membranes in any form or shape ... dyes helps to see antigen being written ...
Medicine Products: